Research Studies for Fatty Liver Disease Announced: Liver Specialists of Texas-UPDATED

Fatty Liver Research

Fatty Liver Research

I am happy to announce that we have three research studies for those suffering from fatty liver disease.

If interested, please call our research staff at the following numbers:

Christina: 713-634-5110
Coby: 713-634-5103
Liver Specialists of Texas Main Number: 713-794-0700
On-Line form: CLICK HERE to send our team at Liver Specialists of Texas a message regarding your interest in the research studies.

Kindly tell them you are interested in the FATTY LIVER RESEARCH STUDIES.

Details of the studies are posted below.

Study 1
A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non Alcoholic Steatohepatitis (NASH) and Fibrosis.

Study 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2b Clinical Trial Evaluating Emricasan, An Orally-Active Pan-Caspase Inhibitor, in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH).

Study 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Part, 12 Week Study to Assess Safety, Tolerability, and Efficacy of LJN452 , in Patients Nonalcoholic Steatohepatitis (NASH).

Each of the three studies have slightly different inclusion criteria, and this will be determined by our research staff to see which study you would best be selected for.

For all of the three research studies, once accepted in the study, all of your medical care related to the study will be free of charge to you. This will include clinic visits, laboratory tests, specific scans, and liver biopsy if needed. All study medicines will be supplied to you. After the study is completed, you will be followed afterwards for an additional several months. Each study will also provide patients with a stipend for each visit that is required. Specific details will be explained is the study documents you will receive if selected.

Here is a short video explaining fatty liver disease in more detail.

Thank you.

Dr. Joe Galati

 

Tags: ,

No comments yet.

Leave a Reply